JP7458973B2 - 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 - Google Patents

新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 Download PDF

Info

Publication number
JP7458973B2
JP7458973B2 JP2020526685A JP2020526685A JP7458973B2 JP 7458973 B2 JP7458973 B2 JP 7458973B2 JP 2020526685 A JP2020526685 A JP 2020526685A JP 2020526685 A JP2020526685 A JP 2020526685A JP 7458973 B2 JP7458973 B2 JP 7458973B2
Authority
JP
Japan
Prior art keywords
seq
antibody molecule
antibody
treg
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526685A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528765A (ja
JP2020528765A5 (enExample
Inventor
フレンデウス ビョルン
モルテンソン リンダ
センリヒ モニカ
テイゲ イングリッド
ベーアス スティーブン
アル－シャムクハニ アイメン
グレイ ジュリエット
グレニー マーティン
Original Assignee
バイオインベント インターナショナル アクティエボラーグ
キャンサー リサーチ テクノロジー リミティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by バイオインベント インターナショナル アクティエボラーグ, キャンサー リサーチ テクノロジー リミティド filed Critical バイオインベント インターナショナル アクティエボラーグ
Publication of JP2020528765A publication Critical patent/JP2020528765A/ja
Publication of JP2020528765A5 publication Critical patent/JP2020528765A5/ja
Priority to JP2023106715A priority Critical patent/JP2023129433A/ja
Application granted granted Critical
Publication of JP7458973B2 publication Critical patent/JP7458973B2/ja
Priority to JP2025116576A priority patent/JP2025157343A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2815—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD8
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020526685A 2017-07-26 2018-07-26 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用 Active JP7458973B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023106715A JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2025116576A JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1712032.0 2017-07-26
GBGB1712032.0A GB201712032D0 (en) 2017-07-26 2017-07-26 Antibodies and uses thereof
PCT/EP2018/070359 WO2019020774A2 (en) 2017-07-26 2018-07-26 NOVEL ANTIBODIES AND COMBINED USE OF ANTIBODY THAT INDUCES TREG DEPLOYMENT AND AN IMMUNOSTIMULATOR ANTIBODY

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023106715A Division JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Publications (3)

Publication Number Publication Date
JP2020528765A JP2020528765A (ja) 2020-10-01
JP2020528765A5 JP2020528765A5 (enExample) 2021-07-26
JP7458973B2 true JP7458973B2 (ja) 2024-04-01

Family

ID=59771732

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020526685A Active JP7458973B2 (ja) 2017-07-26 2018-07-26 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2023106715A Pending JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2025116576A Pending JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023106715A Pending JP2023129433A (ja) 2017-07-26 2023-06-29 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用
JP2025116576A Pending JP2025157343A (ja) 2017-07-26 2025-07-10 新規抗体およびＴｒｅｇ枯渇抗体と免疫刺激性抗体との併用

Country Status (8)

Country Link
US (2) US11447549B2 (enExample)
EP (1) EP3658587A2 (enExample)
JP (3) JP7458973B2 (enExample)
CN (1) CN111108124B (enExample)
AU (1) AU2018305209B2 (enExample)
CA (1) CA3070290A1 (enExample)
GB (1) GB201712032D0 (enExample)
WO (1) WO2019020774A2 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3440109T3 (pl) * 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
GB201712032D0 (en) * 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof
CN111511762B (zh) 2017-08-21 2025-05-06 天演药业公司 抗cd137分子及其用途
WO2019148444A1 (en) 2018-02-02 2019-08-08 Adagene Inc. Anti-ctla4 antibodies and methods of making and using the same
JP7598312B2 (ja) 2018-07-23 2024-12-11 ハイデルベルク ファーマ リサーチ ゲーエムベーハー 同種異系の細胞療法における抗－ｃｄ１３７抗体薬物コンジュゲート（ａｄｃ）の使用
EP3623798B1 (de) * 2018-09-13 2021-11-03 Euroimmun Medizinische Labordiagnostika AG Verfahren und vorrichtung zum erfassen und darstellen eines immunfluoreszenzbildes einer biologischen probe
WO2020216947A1 (en) 2019-04-24 2020-10-29 Heidelberg Pharma Research Gmbh Amatoxin antibody-drug conjugates and uses thereof
US11246906B2 (en) * 2019-06-11 2022-02-15 Alkermes Pharma Ireland Limited Compositions and methods for subcutaneous administration of cancer immunotherapy

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107172880B (zh) * 2014-03-24 2021-09-28 癌症研究技术有限公司 含有修饰IgG2结构域的引起激动或拮抗特性的修饰抗体及其用途
WO2015188047A1 (en) * 2014-06-06 2015-12-10 University Of Maryland, Baltimore ANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
EP3183269A2 (en) * 2014-08-22 2017-06-28 Bristol-Myers Squibb Company Treatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
MA53297A (fr) 2015-03-23 2022-05-04 Jounce Therapeutics Inc Anticorps anti-icos
EP3305322A4 (en) * 2015-06-05 2018-12-26 Chugai Seiyaku Kabushiki Kaisha Combined use of immune activators
EP3303397A1 (en) 2015-06-08 2018-04-11 H. Hoffnabb-La Roche Ag Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
PL3440109T3 (pl) 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
RU2764548C2 (ru) * 2016-08-09 2022-01-18 Кимаб Лимитед Анти-icos антитела
CA3066007A1 (en) 2017-06-09 2018-12-13 Glaxosmithkline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
GB201712032D0 (en) * 2017-07-26 2017-09-06 Bioinvent Int Ab Antibodies and uses thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
M.Remer, et al.，Cancer Immunology Research，2016年，Vol.4, No.11, Supp.，Abstract B046
S.Chen, et al.，Cancer Immunology Research，2015年，Vol.3(2)，p.149-160
Y.Shindo, et al.，ANTICANCER RESEARCH，2015年，Vol.35，p.129-136

Also Published As

Publication number Publication date
WO2019020774A2 (en) 2019-01-31
WO2019020774A3 (en) 2019-05-02
US20200207855A1 (en) 2020-07-02
JP2025157343A (ja) 2025-10-15
CA3070290A1 (en) 2019-01-31
JP2023129433A (ja) 2023-09-14
AU2018305209A1 (en) 2020-02-06
US20230058227A1 (en) 2023-02-23
AU2018305209B2 (en) 2025-06-26
US11447549B2 (en) 2022-09-20
CN111108124B (zh) 2024-09-03
GB201712032D0 (en) 2017-09-06
EP3658587A2 (en) 2020-06-03
CN111108124A (zh) 2020-05-05
JP2020528765A (ja) 2020-10-01

Similar Documents

Publication Publication Date Title
US20230265200A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
US20230058227A1 (en) Novel antibodies and combined use of a treg depleting antibody and an immunostimulatory antibody
US20250163152A1 (en) Compositions comprising a combination of an anti-lag-3 antibody, a pd-1 pathway inhibitor, and an immunotherapeutic agent
CN110248678A (zh) 调节car-t细胞的方法
JP2022537068A (ja) 抗ａｌｐｐ ｃａｒ－ｔ細胞療法
BR112021007995A2 (pt) molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente
JP2020506697A (ja) 改善された抗体結合ｔ細胞受容体構築物およびその治療用途
CA3170020A1 (en) Anti-hpv t cell receptors and engineered cells
TW202216194A (zh) 包含抗ｃｄ１３７抗體之組合療法
EP3617230A1 (en) Novel antibodies and nucleotide sequences, and uses thereof
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
RU2800035C2 (ru) Новая комбинация антител и ее применение
CN119661712A (zh) 特异性结合tnfr2的抗体及其应用
HK40110145A (zh) 新型拮抗性抗tnfr2抗体分子
HK40109442A (en) Novel antagonistic anti tnfr2 antibody molecules
HK40050308B (en) Novel antagonistic anti tnfr2 antibody molecules
HK1262659A1 (en) Anti cd25 fc gamma receptor bispecific antibodies for tumor specific cell depletion
NZ786026A (en) Anti CD25 Fc gamma receptor bispecific antibodies for tumor specific cell depletion

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210610

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210610

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220628

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230228

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230629

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230818

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240111

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240312

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240319

R150 Certificate of patent or registration of utility model

Ref document number: 7458973

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150